These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18793340)

  • 21. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
    Veldhuyzen van Zanten S; Fedorak RN; Lambert J; Cohen L; Vanjaka A
    Am J Gastroenterol; 2003 Sep; 98(9):1963-9. PubMed ID: 14499772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori.
    Qasim A; Sebastian S; Buckley M; O'Connor H; O'Morain C
    Clin Gastroenterol Hepatol; 2004 Jan; 2(1):85; discussion 85. PubMed ID: 15017637
    [No Abstract]   [Full Text] [Related]  

  • 23. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
    Jarbol DE; Kragstrup J; Stovring H; Havelund T; Schaffalitzky de Muckadell OB
    Am J Gastroenterol; 2006 Jun; 101(6):1200-8. PubMed ID: 16771937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
    Liu MK; Wu IC; Lu CY; Kuo CH; Yu FJ; Liu CJ; Hsu PI; Hsu WH; Su YC; Chen A; Wu DC; Kuo FC; Chen JJ
    Kaohsiung J Med Sci; 2013 Jul; 29(7):379-84. PubMed ID: 23768702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.
    Dib J; Alvarez B; Mendez L; Cruz ME
    Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
    Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
    Murakami K; Okimoto T; Kodama M; Sato R; Watanabe K; Fujioka T
    J Clin Gastroenterol; 2008 Feb; 42(2):139-42. PubMed ID: 18209581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
    Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
    Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
    Ang TL; Fock KM; Teo EK; Chan YH; Ng TM; Chua TS; Tan JY
    J Gastroenterol; 2006 Jul; 41(7):647-53. PubMed ID: 16933001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.
    Kate V; Kalayarasan R; Ananthakrishnan N
    Drugs; 2013 Jun; 73(8):815-24. PubMed ID: 23625272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
    Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
    Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Kawamura T; Umehara S; Mori A; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2005 Nov; 84(12):807-11. PubMed ID: 16078036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea.
    Lee JW; Kim N; Kim JM; Nam RH; Kim JY; Lee JY; Lee DH; Jung HC
    Scand J Gastroenterol; 2014 Aug; 49(8):917-24. PubMed ID: 24988873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
    Navarro-Rodriguez T; Silva FM; Barbuti RC; Mattar R; Moraes-Filho JP; de Oliveira MN; Bogsan CS; Chinzon D; Eisig JN
    BMC Gastroenterol; 2013 Mar; 13():56. PubMed ID: 23530767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.